mTOR inhibitors have also repeatedly shown favorable HTN profiles compared to CNIs and therefore have been used for lung transplant populations with post-transplant HTN and for severe pulmonary arterial hypertension (PAH) [106,110]. Here, MTOR is linked to pulmonary arterial hypertension.